Skip to main content
OpenTrials
Completed

NCT Number: NCT02546310

Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive functioning.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Neuroscience and Psychiatry Unit

Manchester, M13 9PT, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy on the basis of medical history, physical examination, vital signs, 12-lead ECG, haematology, blood chemistry, urinalysis and a pre-study psychological assessment.
  • Mini Mental State Examination (MMSE) Score of ≥24.
  • Intermediate or extensive metaboliser as determined by CYP2D6 genotype.
  • Fluent English speaker.
  • Right-handed.
  • Not a regular smoker

Exclusion criteria

  • Recreational drug use within 3 months prior to Screening Visit.
  • Positive alcohol breath test.
  • Positive urine drug screen.
  • Consumption of large amounts of caffeinated drinks.
  • Consumption of any food or any drinks containing cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus fruits or Seville oranges.
  • Ultra-rapid or poor metabolizer as determined by CYP2D6 genotype.
  • By self-report, taking two or more daytime naps per week which in the opinion of the investigator is likely to interfere with the ability of the subject to complete the study procedures.
  • History of, or presents (in the opinion of the Investigator) with, significant neurological or psychiatric conditions.
  • Personal or family history of congenital long QT syndrome or sudden death.
  • Concomitant use of drugs that are metabolised by and/or are inhibitors of CYP2D6.
  • Concomitant use of drugs that are substrates for the organic cation transporter 2.
  • History of significant claustrophobia.
  • Fulfils any of the MRI contraindications on the standard site radiography screening questionnaire (e.g. history of surgery involving metal implants).

Treatment and study plan

HTL0009936

Drug

HTL0009936 matching placebo

Drug

Primary outcomes

  1. Blood oxygen level dependent (BOLD) signal in functional Magnetic Resonance Imaging (fMRI) of the brain areas associated with cognitive tasks

    Time frame: Day 1

Secondary outcomes

  1. BOLD signal in fMRI in other brain regions involved in the regulation of cognitive processes during cognitive tasks

    Time frame: Day 1

  2. cerebral blood flow, assessed using Arterial Spin Labelling (ASL)

    Time frame: Day 1

  3. adverse events

    Time frame: Day 1

  4. blood pressure

    Time frame: Day 1

  5. 12-lead electrocardiogram

    Time frame: Day 1

Other outcomes

  1. event related potentials

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

Nxera Pharma UK Limited

Industry

Collaborators

  • P1vital Limited

Registry information

Official study title

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Sep 10, 2015
Registry last updated
Feb 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.